In colon cancer, RSPO2 and RSPO3 gene fusions have been proposed to potentiate Wnt/β‐catenin signaling, providing a mutational alternative for classical APC and CTNNB1 mutations [7]. This evidence concerns the gene RSPO2 and colonic neoplasm.